A new app created by a Pitt startup aims to reconnect patients with the samples they donate to science through non-fungible tokens (NFTs) and blockchain technology, creating a bridge between the patient’s bedside and laboratory bench.

The idea is to help patients track the research — past and future — being done with their biologic samples, opening up the potential for them to benefit from the scientific discoveries that could improve or save their lives.

During medical visits, patients, especially those suffering from a disease such as cancer, are asked to donate biosamples for research. Once a person consents to research, information that can trace the sample back to its owner is removed — a process known as de-identification. On the surface, this may appear as the safest option for the patient, but, in doing so, they sacrifice the ability to know what happens to their samples and any relevant, resultant discoveries.

Dr. Marielle Gross, assistant professor of obstetrics, gynecology, and reproductive sciences at the University of Pittsburgh, hopes to change that with the development of De-Bi (short for decentralized biobank).

Advertise with us

Gross, who founded heny, Inc., the startup behind De-Bi, wants the app to empower patients as owners of their own biospecimens. The idea materialized when Gross and one of her collaborators, Adrian Lee, were discussing their frustration that researchers often discovered BRCA mutations in de-identified breast samples but could not inform the patient or the patient’s doctor.

“The identity doesn’t need to be known, but the fact that there’s a person on the other side of the equation does,” Gross explains, “and the connection to that person is paramount.” Research is becoming more clinically relevant but lacks a meaningful way to connect the information back to the patient. This is where De-Bi, short for decentralized biobank, steps in to bridge the gap.

The De-Bi app forges relationships between patients and researchers through NFTs and blockchain technology. Patients are reconnected to their biosamples through unique, digital NFTs created from their signed consent forms. The NFTs privately and securely link the patient and their sample. Blockchain technology is then used as a secure digital ledger to track the flow of information between the bench and the bedside.

Once the reconnection is made, the app catalogs patient’s donated samples. Patients then simply click on a specific sample to see if and how it is being used.

But De-Bi is more than a tracking tool; Gross calls it a “citizen science tool.”

Advertise with us
Dr. Marielle Sophia Gross. (UPMC)

Within the app, patients with similar diagnoses can join networks known as “labs.” Not only do the labs provide a sense of community, but they also give members the power to pool their samples as leverage to attract researchers to study their disorders. When researchers use samples from biobanks, they rarely get detailed histories of the samples, such as if they came from family members or patients with a shared environmental exposure. This additional information could be invaluable for researchers and influence their studies. Patient-driven “labs” can provide this supplemental information to assist the scientific process.

As a breast cancer previvor, I understand the value of a bridge between the research bench and the patient’s bedside. My family is at high risk for breast cancer yet negative for all currently known breast cancer genes. De-Bi would allow my family to pool our tissue samples and offer the history and details of our shared cancer. While samples exist from all the diagnosed breast cancer members of my family (and myself as a previvor), researchers do not have access to the collective pool of our samples, nor do they know they are all from one family with an unknown breast cancer gene. This robs scientists of the potential discovery of a new breast cancer gene by studying our tissues. It also keeps my family in the dark about the sinister mutation snaking its way through our family tree.

“It gives me control,” Ramona Nelson, an early user of De-Bi and a breast cancer survivor, explains. “I always felt the more I knew, the more prepared and in control I was.” Nelson wants access to current breast cancer research in the hopes of decreasing lethal lag — the often fatal amount of time between a clinically relevant discovery and when a patient can benefit from that discovery.

De-Bi can decrease lethal lag by linking patients to the information gleaned from their samples, such as what drugs or treatments show promise when used with their tissues. This is the heart of precision medicine — creating individualized treatments for patients based on their unique genetic and molecular makeup.

“At the end of the day, people’s lives could be saved [with] a pathway from the research lab back to the patient,” Gross points out. “And so that’s what we’re building.”

Advertise with us

While the app launched in October as invite-only, Gross and her team recently opened it up. If you are interested in how De-Bi can enable you to track your biosamples, join the pilot program.

Currently, patients (past and present) at the University of Pittsburgh Medical Center can be reconnected to their biosamples. However, patients with donated samples at any institution (hospital or university) can sign up for the waitlist. Over time, Gross hopes to reconnect patients with samples banked at any institution.

Tammy Awtry (drawtry24@gmail.com), Ph.D., is a science communicator and freelance writer based in Colorado Springs, Colorado.